DRG Market Assessment reports

Acute myeloid leukemia (AML) is associated with poor outcomes and low five-year overall survival rates. Although chemotherapy has long been the mainstay of AML treatment, the recent approval of new…

Acute myeloid leukemia (AML) is associated with poor outcomes and low five-year overall survival rates. Although chemotherapy has long been the mainstay of AML treatment, the recent approval of new…

Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, the treatment of AML in China is…

Acute myeloid leukemia (AML) is associated with poor outcomes and low five-year overall survival rates. Although chemotherapy has been the mainstay AML treatment for a long time, the recent…

Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Historically, the prognosis has been poor. Chemotherapy backbones have long dominated treatment, but there is an ongoing…

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Historically, it has had a relatively poor prognosis, including low five-year overall survival rates. Chemotherapy…

Acute myeloid leukemia (AML) is the most common acute leukemia in adults, originating from mutant myeloid precursor cells. Presently, the AML drug market is dominated by chemotherapy backbones, but…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Acute myeloid leukemia patient populations, covering 171 countries…

Clarivate Epidemiology’s coverage of AML comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed incidence and diagnosed…

Clarivate Epidemiology’s coverage of acute myeloid leukemia (AML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of acute myeloid leukemia (AML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…